Clinical trial
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive…
NCT00486356 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00486356 |
|---|---|
| Title | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer |
| Official title | A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Genetic, Other |
| Interventions | capecitabine, carboplatin, epirubicin hydrochloride, microarray analysis, polymorphism analysis, pharmacological study |
| Enrollment | 46 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Jun 14, 2007 |
| Last update posted | Jan 3, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: